Bayer announced that 16 abstracts from studies across its oncology portfolio will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago from May 29–June 2. The presentations span multiple cancer types, including prostate, breast, lung, salivary gland, renal cell, and colorectal cancers.
Key Presentations
Primary results from the Phase II ARACOG (AFT-47) head-to-head trial evaluating NUBEQA (darolutamide) versus enzalutamide in men with metastatic and non-metastatic castration-resistant prostate cancer (CRPC) or metastatic hormone-sensitive prostate cancer (mHSPC) will be presented as an oral abstract. Data from a subgroup post-hoc analysis of the Phase III ARANOTE trial investigating prostate-specific antigen outcomes of NUBEQA plus androgen deprivation therapy (ADT) in patients with metastatic castration-resistant prostate cancer (mCSPC) will also be presented.
Presentations will highlight data from two trials investigating XOFIGO (radium-223 dichloride). Results from the Phase II RADICAL IR-US (Alliance A031801) randomized trial evaluating XOFIGO plus cabozantinib in patients with renal cell carcinoma with bone metastases will be presented as an oral abstract. Data from the Phase II ETCTN 10302 trial investigating XOFIGO in combination with paclitaxel in patients with metastatic breast cancer will be presented as a poster.
Additional Data
Additional presentations include updated safety and efficacy data for HYRNUO (sevabertinib) in patients with advanced HER2-mutant non-small cell lung cancer, efficacy and safety data for VITRAKVI (larotrectinib) in patients with non-primary central nervous system TRK fusion cancer, and real-world experience with larotrectinib in pediatric extracranial NTRK fusion–positive tumors. The portfolio also includes evaluation of regorafenib combined with avelumab in patients with HPV-associated cancer through the Phase II REGOMUNE study.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.timesargus.com/news/business/asco-2026-bayer-to-present-new-data-across-oncology-portfolio/article_b6d1e045-263b-5ceb-8ad5-847e6824300a.html